FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

Download PDF Copy

Apr 9 2014

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. Teva believes it is first-to-file and thus far is the only Company to receive an approval from FDA. Teva plans to commence shipping immediately.

Lovaza® Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the United States, according to IMS data as of December 2013.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

New treatment approach developed to prevent lupus nephritis

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Edible microbeads trap fat to support weight loss

New study reveals long road to seizure control for people with focal epilepsy

WHO expands global network of trusted medical product regulators

COPD care pathways improve hospital outcomes and standardize treatment

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.